Table 3.

Monitoring of Patients on Siponimod per FDA Recommendations.^48–50,88

Potential Adverse Event	Monitoring Test
Lymphopenia	Complete blood count at 3–6 months after initiation then every 6–12 months thereafter
Hypertension	Monitor BP regularly during treatment
Macular Edema	Ophthalmologic evaluation if visual symptoms occur or after 3–4 months for patients with diabetes and uveitis.
Dyspnea	Pulmonary function test (spirometry) if respiratory symptoms occur
Liver Injury	Liver enzymes testing after 3–6 months after initiation then every 6–12 months thereafter
Fetal Risk	Evaluation of use of effective contraception during treatment with siponimod and up to 10 days after discontinuation